Inclusion Criteria:

  • Male or female who are 18 years of age or older on the day of signing informed consent
  • Subjects completed one of the qualifying core studies GLPG0634-CL-203 or GLPG0634-CL-204 and who may benefit from GLPG0634 long-term treatment according to the Investigator's judgment
  • Females of childbearing potential and sexually active men must agree to use highly effective method of birth control as specified in the protocol, during the study and for at least 12 weeks after the last dose of GLPG0634

Exclusion Criteria:

  • Subjects prematurely withdrawn from one of the 2 core studies (GLPG0634-CL-203 or GLPG0634-CL-204), for any reason
  • Persistent abnormal lab values during one of the 2 core studies (GLPG0634-CL-203 or GLPG0634-CL-204), according to the Investigator's judgment
  • Diagnosis of rheumatic autoimmune disease or inflammatory joint disease other than rheumatoid arthritis, except for secondary Sjogren's syndrome
  • Any condition or circumstances which, in the opinion of the Investigator, may make a subject unlikely or unable to complete the study or comply with study procedures and requirements

Read more: http://www.clinicaltrials.gov/ct2/show/NCT02065700?cond=%22Arthritis%22&lup_s=01/29/2014&lup_d=30